Faralimomab, identified by the CAS number 167816-91-3, is a monoclonal antibody that has been investigated for its potential therapeutic applications, particularly in the treatment of autoimmune diseases. As a biologic, it is designed to target specific proteins in the immune system, modulating immune responses to reduce inflammation and tissue damage. Faralimomab exhibits high specificity and affinity for its target, which contributes to its efficacy and safety profile. The substance is typically administered via injection, and its pharmacokinetics can vary based on factors such as dosage and patient characteristics. Like other monoclonal antibodies, Faralimomab may have side effects, including infusion reactions and potential immunogenicity. Its development and clinical use are subject to rigorous regulatory scrutiny to ensure safety and effectiveness. Overall, Faralimomab represents a significant advancement in targeted therapies for conditions characterized by dysregulated immune responses.

Faralimomab

167816-91-3: Faralimomab, identified by the CAS number 167816-91-3, is a monoclonal antibody that has been investigated for its potential therapeutic applications, particularly in the treatment of autoimmune diseases. As a biologic, it is designed to target specific proteins in the immune system, modulating immune responses to reduce inflammation and tissue damage. Faralimomab exhibits high specificity and affinity for its target, which contributes to its efficacy and safety profile. The substance is typically administered via injection, and its pharmacokinetics can vary based on factors such as dosage and patient characteristics. Like other monoclonal antibodies, Faralimomab may have side effects, including infusion reactions and potential immunogenicity. Its development and clinical use are subject to rigorous regulatory scrutiny to ensure safety and effectiveness. Overall, Faralimomab represents a significant advancement in targeted therapies for conditions characterized by dysregulated immune responses.

<p>A murine anti-IFNA1 IgG1 mouse monoclonal antibody</p>

<p>Faralimomab (64G12) is an immunomodulator, and a murine anti- IFNA1 IgG1 mAb [1] .</p>

CAS 167816-91-3

Faralimomab

Faralimomab

Ref: 3D-CLA1227

Faralimomab

Ref: TM-T77004